I'm Guilty
A few months ago, before the April conference when Harvey alluded to more compounds, I posted a list of predictions as to what we could be looking forward to for the remainder of the year. One of those predictions was the announcement of a fourth compound.
Harvey's statement in April confirmed (at least to me) that this prediction of mine will probably bear fruit this year. When I published my post, I did not, for a minute, mean to imply that a fourth compound would have any initial effect on the PPS. I see, however, that some posters on this board are almost upset with the idea of the introduction of another compound, reasoning that Ariad must concentrate on our present robust pipeline. To those posters I advance the following:
1- Ariad obviously has a very effecient and productive R&D team. Do you really think that the company will stiffel their inventiveness because we have several very promising candidates to becoming meaningful cancer drugs?
2- I am sure that this R&D team spends almost no time on helping Ariad march Rida, Pona and 113 through the clinical process. I am sure they are busy at work and very proud of their contributions to the company. Their work certainly does not interfere with, or take away any concentration from the process of having Rida, Pona & 113 gain access to the marketplace.
3- The pipeline of a Bio is the compounds that they deveolop and or acquire and I am sure that their good science will continue.
4- Eventually I see Ariad as a drug discoverer, a company with expertise in bringing their drugs through the clinical process and brought to market, a drug manufacturer and a Pharmacy company that specializes in selling oncology products. This is what I believe Harvey has in mind and in store for Ariad.
I will predict it once again. Ariad will announce a fourth compound in 2011.
As usual this is JMHO,
Barry
